A Study of Setmelanotide in Patients With Prader-Willi Syndrome
← catalyst calendarNCT06772597 · readout in 73 d
Sponsored by Rhythm Pharmaceuticals, Inc. (industry) · RYTM — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-04 | actual | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Prader-Willi Syndrome
- Obesity
- Hyperphagia
Intervention
- Drug: Setmelanotide — also filed as Imcivree
Primary outcome
what the primary-completion date above is the date OFFrequency and severity of adverse events (AEs)
measured Baseline to Week 52
Permalink · RYTM's whole pipeline · Catalyst calendar · Every registered study · What changed